版本:
中国

BRIEF- Aerie says Roclatan successfully achieves primary efficacy endpoint in Mercury 1 study

Sept 14 Aerie Pharmaceuticals Inc

* Aerie pharmaceuticals reports positive roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% phase 3 topline efficacy results

* Oclatan ( TM ) successfully achieves primary efficacy endpoint in mercury 1 study

* Expect to file NDA for roclatan near year-end 2017 Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐